For research use only. Not for therapeutic Use.
Cefodizime Sodium（Cat No.:I018292）is a broad-spectrum third-generation cephalosporin antibiotic, designed for the treatment of bacterial infections. It works by inhibiting the synthesis of bacterial cell walls, leading to cell lysis and the death of the pathogen. Cefodizime sodium is effective against a wide range of Gram-positive and Gram-negative bacteria, including those resistant to other antibiotics. It is commonly used in treating respiratory tract infections, urinary tract infections, and soft tissue infections. With high stability against β-lactamase enzymes, Cefodizime Sodium offers a reliable option for clinical infection management.
| Catalog Number | I018292 |
| CAS Number | 86329-79-5 |
| Molecular Formula | C₂₀H₁₈N₆Na₂O₇S₄ |
| Purity | ≥95% |
| Target | Penicillin-binding protein (PBP) |
| IUPAC Name | disodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxylatomethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| InChI | InChI=1S/C20H20N6O7S4.2Na/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9;;/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32);;/q;2*+1/p-2/b25-12-;;/t13-,17-;;/m1../s1 |
| InChIKey | WBOBLQIRACJNPA-AEKYOGSZSA-L |
| SMILES | CC1=C(SC(=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-])CC(=O)[O-].[Na+].[Na+] |
| Reference | [1]. Barradell LB, et al. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1992 Nov;44(5):800-34.<br>[2]. Hu T, et al. Probing the interaction of cefodizime with human serum albumin using multi-spectroscopic and molecular docking techniques. J Pharm Biomed Anal. 2015 Mar 25;107:325-32. |
